This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Antitumor activity of the protein kinase inhibitor 1-(β-D-2′-deoxyribofuranosyl)-4,5,6,7-tetrabromo- 1H-benzimidazole in breast cancer cell lines
BMC Cancer Open Access 15 October 2022
-
Protein kinase CK2: a potential therapeutic target for diverse human diseases
Signal Transduction and Targeted Therapy Open Access 17 May 2021
-
Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia
BMC Cancer Open Access 06 March 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Heisterkamp N, Groffen J . BCR/ABL gene structure and BCR function. In: Carella AM, Daley GQ, Eaves CM, Goldman JM, Hehlman R (eds). Chronic Myeloid Leukemia: Biology and Treatment. Martin Dunitz Ltd: UK, 2001, pp 3–17.
Deininger M, Buchdunger E, Druker BJ . The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640–2653.
Hofmann WK, Komor M, Hoelzer D, Ottmann OG . Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia. Leuk Lymphoma 2004; 45: 655–660.
Ren R . Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5: 172–183.
Mishra S, Reichert A, Cunnick J, Senadheera D, Hemmeryckx B, Heisterkamp N et al. Protein kinase CKIIalpha interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells. Oncogene 2003; 22: 8255–8262.
Tawfic S, Yu S, Wang H, Faust R, Davis A, Ahmed K . Protein kinase CK2 signal in neoplasia. Histol. Histopathol 2001; 16: 573–582.
Piazza F, Ruzzene M, Gurrieri C, Montini B, Bonanni L, Chioetto G et al. Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood 2006; 108: 1698–1707.
Pagano MA, Meggio F, Ruzzene M, Andrzejewska M, Kazimierczuk Z, Pinna LA . 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. Biochem Biophys Res Commun 2004; 321: 1040–1044.
Acknowledgements
We thank Jess Cunnick for advice and help with the leukemia–MEF co-culture system. This work was supported by PHS Grant CA90321 (NH), the Kenneth T and Eileen L Norris Foundation (SM, VP, BZ, PK, JG) and the TJ Martell Foundation (JG and NH) and by AIRC and Integrated EU Project ‘Orokinase Research’ LSHB-CT-2004-503467 (LAP).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mishra, S., Pertz, V., Zhang, B. et al. Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2. Leukemia 21, 178–180 (2007). https://doi.org/10.1038/sj.leu.2404460
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404460
This article is cited by
-
Antitumor activity of the protein kinase inhibitor 1-(β-D-2′-deoxyribofuranosyl)-4,5,6,7-tetrabromo- 1H-benzimidazole in breast cancer cell lines
BMC Cancer (2022)
-
Protein kinase CK2: a potential therapeutic target for diverse human diseases
Signal Transduction and Targeted Therapy (2021)
-
Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia
BMC Cancer (2019)
-
Therapeutic targeting of CK2 in acute and chronic leukemias
Leukemia (2018)
-
Targeting CK2-driven non-oncogene addiction in B-cell tumors
Oncogene (2016)